| 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study TR Malaba, I Nakatudde, K Kintu, A Colbers, T Chen, H Reynolds, L Read, ... The Lancet HIV 9 (8), e534-e543, 2022 | 35 | 2022 |
| Leveraging investments in Ebola preparedness for COVID-19 in Sub-Saharan Africa R Ayebare, P Waitt, S Okello, M Kayiira, MA Ajok, I Nakatudde, ... AAS open research 3, 2020 | 21 | 2020 |
| Vaccination timeliness and associated factors among preterm infants at a tertiary hospital in Uganda I Nakatudde, J Rujumba, F Namiiro, A Sam, J Mugalu, P Musoke PloS one 14 (9), e0221902, 2019 | 19 | 2019 |
| It is not always Tuberculosis! A case of pulmonary cryptococcosis in an immunocompetent child in Uganda I Nakatudde, P Kasirye, S Kiguli, P Musoke African Health Sciences 21 (3), 990-994, 2021 | 8 | 2021 |
| Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir-based antiretroviral therapy start in Kampala, Uganda I Nakatudde, E Katana, EL Agnes Odongpiny, EA Nalugga, ... AIDS Research and Therapy 21 (1), 1-11, 2024 | 1 | 2024 |
| Leveraging investments in Ebola preparedness for COVID-19 in R Ayebare, P Waitt, S Okello, M Kayiira, MA Ajok, I Nakatudde, ... | | 2020 |
| Sub-Saharan Africa [version 1; peer review: awaiting peer R Ayebare, P Waitt, S Okello, M Kayiira, MA Ajok, I Nakatudde, ... | | |
